Dosing reference
Every dose that has been studied in humans
Label dosing for approved drugs, the amounts given in registered trials of investigational drugs, and a plain “none established” everywhere else. No forum numbers, no vendor charts. Every figure cites its source.
22 · FDA label15 · Trial doses71 · None established
Reconstitution guide
Lab steps with photos, syringe units and storage.
How long studies ran
Cycle-length evidence: treatment and follow-up durations.
Combinations
What is actually studied when compounds are paired.
Human dosing quick-reference chart
Click any compound for the cited dosing page, study durations and vial arithmetic.
| Compound | Research area | Status | Human amounts | Route studied | Half-life | Evidence | |
|---|---|---|---|---|---|---|---|
| Afamelanotide | Skin | FDA-approved | 16 mg afamelanotide per implant (FDA label) | Subcutaneous implant inserted by a trained health care professional | Approximately 15 hours (apparent, from the implant) | A | View |
| Argireline | Skin | Not approved | None established | — | Not located in the sources reviewed. Related work on cosmetic peptides reports rapid degradation in skin extracts, but no half-life for this peptide in humans was identified . | B | View |
| GHK-Cu | Skin | Not approved | None established | — | — | B | View |
| Matrixyl | Skin | Not approved | None established | — | Not located in the sources reviewed. In skin extracts and homogenates both the unmodified pentapeptide and the palmitoylated form were rapidly degraded, with the palmitoylated form more stable; protease inhibitors improved the stability of both (mouse skin preparations) . | B | View |
| Melanotan I | Skin | Not approved | None established | — | — | — | View |
| Melanotan II | Skin | Not approved | None established | — | — | B | View |
| SNAP-8 | Skin | Not approved | None established | — | — | — | View |
“Human amounts” is a summary; the dosing page for each compound carries the full cited statements. Compounds approved nowhere show “None established” by policy, whatever is circulated elsewhere. Why.
What every dosing page includes
- Quick-reference card
- Label or trial doses, cited
- How long studies ran
- Who was excluded
- Side effects reported
- Reconstitution arithmetic + syringe chart
- Supplies, storage and handling mistakes
- Regulatory status
- Comparison with related compounds
- Combinations and FAQs
Don’t see a compound?
Tell us what to research next. We add compounds when there are primary sources to cite.